對 Cereblon E3 連接酶調變器(CELMoD) 的全球臨床試驗和市場機會的洞察 (2026)

《Cereblon E3 連接酶調變器(CELMoDs) 全球臨床試驗和市場機會洞察 (2026)》報告的亮點和發現：

• 調查方法
• 首款 cereblon E3 連接酶調變器劑藥物預計將於 2030 年上市。
• Cereblon E3連接酶調變器製劑的市場重要性
• 臨床試驗中 Cerebron E3 連接酶調變器藥物的最新進展：超過 20 種藥物
• 按公司、國家、適應症和階段分類的 Cerebron E3 連接酶調變器臨床試驗概況
• 主要藥物臨床試驗的啟動和完成歷時數年
• 當前發展狀況及未來機會展望
• 競爭格局

CELMoD標靶治療的必要性及本報告的意義

全球cereblon E3連接酶調變器（CELMoD）市場已從科學發現階段發展成為標靶蛋白水解和免疫腫瘤學領域高度成熟的臨床階段。 CELMoD是新一代免疫調節劑，旨在以更高的選擇性和效力改善cereblon介導的蛋白水解過程。 CELMoD藥物透過分解IKZF1和IKZF3等轉錄因子，恢復免疫監視功能並發揮抗腫瘤活性，尤其是包括多發性骨髓瘤在內的血液系統惡性腫瘤。與上一代免疫調節劑（IMiD）相比，新一代CELMoD具有更優異的cereblon結合特性和更強的免疫活化作用。

截至2026年6月，尚無任何CELMoD類藥物獲得全面監管核准，但其研發管線在臨床試驗進展方面正處於轉捩點。伊維達胺、美地度胺和戈爾卡胺等藥物已進入III期臨床試驗，目前人們對單株抗體聯合治療越來越感興趣。伊維達胺尤其在該類藥物的臨床開發中發揮了關鍵作用，在III期臨床試驗中展現出深度緩解，包括微小殘留病灶（MRD）陰性後，已符合復發或難治性多發性骨髓瘤的上市申請條件。 CELMoD類藥物已從臨床前階段邁向接近商業化階段，是腫瘤學領域最令人矚目、最有前景的新藥類別之一。

本報告旨在為投資者、製藥公司及其他對此領域感興趣的相關人員提供關於腦蛋白調節技術現狀的系統分析。報告評估了腦蛋白調節領域的科學進展、臨床開發趨勢、競爭格局和商業策略趨勢。鑑於該領域的快速發展，本報告不僅闡明了當前的臨床狀況，還對這些治療方法的未來發展方向提供了見解。

本報告中包含對臨床試驗的深入分析

CELMoD 的治療研究主要基於目前針對血液系統惡性腫瘤（尤其是復發或難治性多發性骨髓瘤）的臨床試驗，這些領域仍存在巨大的未滿足醫療需求。目前 CELMoD 的臨床試驗包括與現有核心療法（例如 CD38 抗體、蛋白酶體抑制劑和類固醇）合併治療。聯合治療是目前研究的前沿方向，因為它不僅可以最大限度地激活免疫反應，還可以解決導致現有藥物抗藥性的機制。臨床試驗一致表明，CELMoD 比傳統免疫調節劑更有效，並且能夠延長緩解持續時間。

然而，CELMoD 不僅在多發性骨髓瘤中進行測試，還在其他血液系統惡性腫瘤（如淋巴瘤）以及某些固體癌（如腎細胞癌）中進行測試。儘管血液系統惡性腫瘤仍然是 CELMoD 研發管線的主要目標，但這些探索性臨床試驗表明，cereblon 調節劑也可用於治療其他類型的癌症。臨床試驗種類日益增多，包括適應性試驗和基於生物標記篩選的隊列研究，這表明腫瘤學研究正朝著精準方向發展。

推動CELMoD研發的領導企業

目前，CELMoD領域的領導企業包括多家擁有免疫腫瘤學研發管線的大型製藥公司。百時美施貴寶是CELMoD領域臨床開發的領導企業之一，其研發管線包括伊維達胺、美地度胺、戈爾卡胺以及其他幾種處於早期開發階段的化合物。特別是伊維達胺，目前正在多種治療方案中進行評估，這表明該公司的策略是將這種腦橋蛋白調變器整合到多種現有癌症治療方案中。伊維達胺獲得監管部門核准，鞏固了該公司在全球CELMoD市場的地位。

除了大型製藥公司外，生技公司也開始在該領域做出重大貢獻。例如，C4 Therapeutics 等公司正致力於開發新一代 cereblon調變器和分子黏合劑分解劑，以拓展蛋白質標靶的範圍。此外，不同組織之間的策略聯盟在 CELMoD 藥物的研發中發揮著至關重要的作用。特別是，透過人工智慧驅動的藥物發現平台整合運算生物學和 cereblon 研究，並與藥物研發專家合作，是加速研發進程的關鍵策略。

CELMoD標靶治療的未來前景

CELMoD 的未來研究方向包括探索其在更廣泛的疾病相關蛋白中的應用，而不僅限於轉錄因子。此外，cereblon 修飾和分子膠技術的進步使研究人員能夠探索其他分解途徑，從而拓展 CELMoD 的潛在應用。人工智慧和體學技術在這些研究中正變得日益重要，因為它們能夠發現新的標靶並簡化藥物研發流程。

聯合治療預計將在CELMoD的研發中繼續發揮重要作用，尤其是在癌症治療的早期階段。隨著臨床數據的積累，CELMoD有望很快與其他免疫腫瘤藥物和標靶治療聯合作為一線治療方案。基於生物標記的患者分層也是一個很有前景的研究領域，因為它可以透過精準醫療方法來提高治療效果。

目錄

• 表2-1：TPD抑制劑與傳統抑制劑的比較
• 表 2-2：TPD 中具有臨床意義的 E3 連接酶
• 表2-3：IMiDs和CELMoDs的比較
• 表 2-4：CELMoD 在腫瘤學領域的競爭定位
• 表 3-1：IMiDs、CELMoDs 和 PROTACs 的比較

Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials & Market Opportunity Insight 2026 Report Highlights & Findings:

• Research Methodology
• First Cereblon E3 Ligase Modulator Drug Expected By 2030
• Market Relevance Of Cereblon E3 Ligase Modulators Drugs
• Insight On Cereblon E3 Ligase Modulator Drugs In Clinical Trials: > 20 Drugs
• Cereblon E3 Ligase Modulators Clinical Trials Insight By Company, Country, Indication & Phase
• Key Drugs Clinical Study Initiation & Completion Year
• Current Development Scenario & Future Opportunity Outlook
• Competitive Landscape

Need For CELMoD Targeting Therapies & Why This Report?

The global Cereblon E3 Ligase Modulators (CELMoDs) market has evolved from the realm of scientific discovery to become a highly advanced clinical-stage segment within targeted protein degradation and immuno-oncology. CELMoDs are the next generation of immunomodulatory drugs that aim to improve the Cereblon mediated protein degradation process with higher selectivity and potency. Through the process of degradation of transcription factors such as IKZF1 and IKZF3, CELMoD drugs restore immune surveillance and generate anti-tumor activity, especially in hematologic cancers including multiple myeloma. The current generation of CELMoDs shows better cereblon binding properties and increased immune activation compared to the previous generation of IMiDs.

As of June 2026, there is no CELMoD that has gained full regulatory approval, but the pipeline has now reached a turning point in terms of progress in clinical trials. There are some agents such as iberdomide, mezigdomide, and golcadomide that have progressed to pivotal stages, with attention now increasingly shifting towards combination treatments using monoclonal antibodies and corticosteroids. Iberdomide has been especially important in terms of the clinical development of this class, with regulatory filings for relapsed or refractory multiple myeloma having been made possible due to deep responses observed in the Phase 3 study of the candidate, including negative results for measurable residual disease. This move from preclinical biology to near-commercialization makes CELMoDs one of the most interesting and exciting new classes of drugs in the field of oncology.

The purpose of this report is to offer a systematic analysis of the landscape of cereblon modulation technology for investors, pharmaceutical companies, and other parties with an interest in the sector. The report offers an assessment of scientific advances, clinical development trends, competitive dynamics, and commercial strategy trends in the field of cereblon modulation. With rapid advancements in the field, the report not only highlights the present clinical situation but also provides an insight into the future direction of these therapies.

Clinical Trials Insight Included In Report

CELMoD therapeutic research is largely based on current clinical investigations in hematological cancers, especially relapsed and refractory multiple myeloma where there is still significant unmet medical need. Current clinical investigations for CELMoDs include their use in combination with existing backbone therapies such as CD38 antibodies, proteasome inhibitors, and steroids. Combination therapies are at the forefront of current research activities since they not only maximize immune activation but also tackle mechanisms that cause resistance to existing drugs. Clinical trials show a consistent trend whereby CELMoDs are more effective and lead to prolonged responses than previous immunomodulatory drugs.

However, apart from being tested in multiple myeloma, CELMoDs have also been tested in other hematologic tumors such as lymphomas and certain solid tumors like renal cell carcinomas. Although hematologic cancers remain the primary focus of the CELMoD pipeline, these exploratory clinical investigations indicate the belief that the cereblon modulating drugs can be used to treat other forms of cancer too. The increased number of clinical trial types, such as adaptive studies and biomarker-selected cohorts, indicates the shift towards precision oncology research.

Major Companies Driving CELMoD Research & Development

The current leading organizations in the CELMoD space include a select few large pharmaceutical companies that possess immuno-oncology pipelines. Bristol Myers Squibb is one of the leaders of clinical developments in the CELMoD space with a pipeline that consists of iberdomide, mezigdomide, golcadomide, and several other compounds that are in the early stages of development. Iberdomide, in particular, is undergoing evaluation in numerous lines of treatment, which suggests that the organization's strategy is to integrate the modulators of cereblon into various existing oncology treatments. The regulatory acceptance of iberdomide has reinforced the firm's position within the global CELMoD market.

In addition to large pharmaceutical companies, biotechnology firms have started making significant contributions to the field. Organizations such as C4 Therapeutics are working on developing next-generation cereblon modulators and molecular glue degraders for expanding the range of protein targets. In addition, strategic collaborations between different organizations play a crucial role in the development of the CELMoD drugs. In particular, the integration of computational biology and cereblon research through collaboration with AI-based discovery platforms and drug development experts is a key strategy for accelerating the process.

Future Outlook For CELMoD Targeting Therapies

The future directions for CELMoD research will include exploration beyond the use of transcription factors as the targets for cellular proteolysis to a greater number of disease-causing proteins. In addition, advances in cereblon modification and molecular glue technologies allow researchers to explore other degradation routes, thus extending the range of potential applications for CELMoDs. Artificial intelligence and omics technologies are gaining in importance in such research due to their ability to find novel targets and streamline drug discovery.

The use of combination therapies will also likely continue to play an important role in the development of CELMoDs, especially in the early lines of cancer therapy. With more clinical data being generated, CELMoDs may soon find their way into the first-line treatment along with other immune-oncology drugs and targeted therapies. Patient stratification based on biomarkers is another promising avenue of research, as it can help improve treatment efficacy through precision medicine approaches.

Table of Contents

• Table 2-1: TPD vs. Conventional Inhibitors
• Table 2-2: Clinically Relevant E3 Ligases In TPD
• Table 2-3: IMiDs vs CELMoDs Comparison
• Table 2-4: Competitive Positioning Of CELMoDs In Oncology
• Table 3-1: IMiDs vs CELMoDs vs PROTACs

List of Figures

• Figure 2-1: Ubiquitin Proteasome System Overview
• Figure 2-2: Evolution Of Cancer Therapy: From Chemotherapy To Targeted Protein Degradation
• Figure 2-3: Key Advantages Of TPD
• Figure 2-4: Evolution Of CRBN - Based Therapeutics Timeline
• Figure 2-5: Mechanism Of IMiD/CELMoD-Induced Protein Degradation
• Figure 2-6: CRBN Signaling In Multiple Myeloma
• Figure 2-7: Targeted Protein Degradation Expands The Druggable Proteome
• Figure 2-8: Elderly & Comorbid Patient Care Positioning
• Figure 3-1: CELMoD Evolution: From IMiDs To Next Generation CELMoDs
• Figure 3-2: Event-Driven vs. Occupancy-Driven Pharmacology
• Figure 3-3: Multi-Layer Anti-Tumor Mechanism Of CELMODs
• Figure 3-4: Canonical Ubiquitination Cascade
• Figure 3-5: Structure Of CRL4CRBN Complex
• Figure 3-6: UPS Crosstalk & Therapeutic Exploitation
• Figure 3-7: Advantages Of CELMoDs Over Earlier Imids
• Figure 3-8: Why CELMoDs Are Considered Next-Generation Molecular Glues
• Figure 4-1: Molecular Glue Mechanism Of CELMoDa
• Figure 4-2: Conformational Dynamics Of CRBN
• Figure 4-3: Immediate vs Delayed Biological Effects Of CELMoDs
• Figure 4-4: Mechanisms Of Resistance To CELMoDs
• Figure 4-5: Response vs. Resistance
• Figure 5-1: Global CELMoDs Market - Future Opportunities
• Figure 6-1: EXCALIBER-RRMM Phase 3 (NCT04975997) Study - Initiation & Completion Year
• Figure 6-2: EXCALIBER-Maintenance Phase 3 (NCT05827016) Study - Initiation & Completion Year
• Figure 6-3: MagnetisMM-30 Phase 1 (NCT06215118) Study - Initiation & Completion Year
• Figure 6-4: SUCCESSOR-2 Phase 3 (NCT05552976) Study - Initiation & Completion Year
• Figure 6-5: SUCCESSOR-1 Phase 3 (NCT05519085) Study - Initiation & Completion Year
• Figure 6-6: CC-99282-NHL-001 Phase 1/2 (NCT03930953) Study - Initiation & Completion Year
• Figure 6-7: 25-229 Phase 1/2 (NCT07356154) Study - Initiation & Completion Year
• Figure 6-8: CA236-0001 Phase 1/2 (NCT06697197) Study - Initiation & Completion Year
• Figure 6-9: CA230-1019 Phase 1/2 (NCT06481306) Study - Initiation & Completion Year
• Figure 6-10: Autoimmune & Inflammatory Diseases - Immune & Inflammatory Outcomes Of CELMoDs
• Figure 6-11: CC-90009 (Eragidomide) Antiviral Mechanism
• Figure 8-1: Global - Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Phase, 2026
• Figure 8-2: Global - Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Country, 2026
• Figure 8-3: Global - Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Company, 2026
• Figure 8-4: Global - Number Of Cereblon E3 Ligase Modulators (CELMoDs) In Clinical Trials By Indication, 2026
• Figure 10-1: Global CELMoDs Market - Drivers & Opportunities

List of Tables

1. Research Methodology

2. Introduction To Cereblon E3 Ligase Modulators (CELMoDs)

• 2.1 Overview Of Targeted Protein Degradation (TPD) Landscape
• 2.2 Evolution Of CRBN Based Therapeutics (IMiDs To CELMoDs)
• 2.3 Market Relevance & Unmet Needs In Oncology & Beyond

3. Basics of Cereblon E3 Ligase Modulators (CELMoDs) Biology

• 3.1 Definition & Core Concept Of CELMoDs
• 3.2 CRBN Complex & Protein Degradation Pathway (Ubiquitin-Proteasome System)
• 3.3 Positioning Within TPD: IMiDs vs CELMoDs vs PROTACs

4. Mechanism of Action & Drug Class Characteristics

• 4.1 CRBN Mediated Molecular Glue Mechanism
• 4.2 Target Protein Degradation & Downstream Effects
• 4.3 Therapeutic Outcomes & Resistance Mechanisms

5. Global Cereblon E3 Ligase Modulators (CELMoDs) Market Overview

• 5.1 Current Clinical Development & Market Scenario
• 5.2 Future Market Outlook

6. Cereblon E3 Ligase Modulators (CELMoDs) - Clinical Development Trends By Indication

• 6.1 Cancer
  • 6.1.1 Hematological Malignancies
  • 6.1.2 Solid Cancers
• 6.2 Hematological Disorders
• 6.3 Autoimmune & Inflammatory Diseases
• 6.4 Microbial Infections

7. Cereblon E3 Ligase Modulators (CELMoDs) Development Analysis By Region

• 7.1 US
• 7.2 Europe
• 7.3 China

8. Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials Overview

• 8.1 By Phase
• 8.2 By Country
• 8.3 By Company
• 8.4 By Indication

9. Global Cereblon E3 Ligase Modulators (CELMoDs) Clinical Trials Insight By Company, Country, Indication & Phase

• 9.1 Preclinical
• 9.2 Phase I
• 9.3 Phase I/II
• 9.4 Phase II
• 9.5 Phase III
• 9.6 Preregistration

10. Global Cereblon E3 Ligase Modulators (CELMoDs) Market Dynamics

• 10.1 Market Drivers & Opportunities
• 10.2 Challenges & Strategic Solutions

11. Competitive Landscape

• 11.1 BioTheryX
• 11.2 Bristol Myers Squibb
• 11.3 C4 Therapeutics
• 11.4 Chia Tai Tianqing Pharmaceutical Group
• 11.5 Decoy Therapeutics
• 11.6 Degron Therapeutics
• 11.7 Evotec
• 11.8 GluBio Therapeutics
• 11.9 Gluetacs Therapeutics
• 11.10 Kangpu Biopharmaceuticals